This compound works by reducing magnesium levels in mitochondria generation plants – which supports the ongoing energy burning instead of slowing it down.
A research group from Texas, Pennsylvania and Cornell universities allowed to develop this pharmaceutical compound, which they called CPACC, which imitates the influence of the removal of the MRS2 gene responsible for the transfer of magnesium in mitochondria.
When the magnesium levels in these cellular mitochondria are reduced, cell effectiveness increases significantly in burning sugar and fats, which was clearly observed in experiments conducted on mice. Surprisingly, the mice that received treatment remained completely thin and healthy, despite their food with a high diet for a long time, without any signs of a fat liver disease, which usually accompanies such a diet.
Professor Madish Monnesva, the leader of the research group, explained that this drug can be a real boom in preventing a group of metabolic and heart disease that arise as a result of obesity and malnutrition.
In his statement, he said: “When we give this medicine to mice for a short period of time, you begin to lose weight until they become thin.” But the most important of simple weight loss is the ability of this drug to reduce the risk of dangerous diseases associated with obesity, such as heart attacks and strokes, and even the prevention of liver cancer, which can develop in case of chronic fat cases of the liver.
The study, which lasted for several years and published its results in cell reports, revealed a completely new aspect of the role of magnesium in metabolism. In contrast to the prevailing belief that an increase in magnesium is always useful, the researchers found that its high level inside mitochondria acts as a “brake”, slowing down energy production. This fundamental discovery led the team to develop the CPACC molecule, which limits the transfer of magnesium to mitochondria, which maintains the continuity of the energy production process with high efficiency.
It is worth noting that the University of Texas has already submitted a patent request for this promising medicine, while the research group seeks to continue its development and study its consequences in the long term.
This innovation is the fruit of outstanding scientific cooperation between several outstanding research institutes, since scientists from the University of Pennsylvania contributed to the design of the molecules, while Cornell’s researchers took the chemical production task.
Despite these impressive results, researchers warn that the road long before this drug is available for use by a person, since it needs more research and clinical experiments. But there is no doubt that this scientific study opens up new horizons in the treatment of obesity and related diseases, and once it can be a radical solution to one of the biggest health problems that humanity faces in the modern era.
Source: ScitechDail
